Cardiol Therapeutics Files 6-K with April News Release

Ticker: CRDL · Form: 6-K · Filed: Apr 1, 2025 · CIK: 1702123

Sentiment: neutral

Topics: filing, news-release, sec

TL;DR

Cardiol Therapeutics filed a 6-K on April 1st, including a news release. Stay tuned for updates.

AI Summary

Cardiol Therapeutics Inc. filed a Form 6-K on April 1, 2025, reporting for the month of April 2025. The filing includes a news release dated April 1, 2025, as Exhibit 99.1. The company is incorporated in Canada and its principal executive offices are located in Oakville, Ontario.

Why It Matters

This filing indicates ongoing corporate activity and communication from Cardiol Therapeutics Inc. to the SEC, potentially including important updates for investors.

Risk Assessment

Risk Level: low — This is a routine filing (6-K) that primarily serves to submit a news release, with no immediate indication of significant financial or operational changes.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K filing is to report for the month of April 2025 and to submit a news release dated April 1, 2025, as Exhibit 99.1.

What is the filing date of this Form 6-K?

This Form 6-K was filed on April 1, 2025.

Where are Cardiol Therapeutics Inc.'s principal executive offices located?

Cardiol Therapeutics Inc.'s principal executive offices are located at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5.

What is the Commission File Number for Cardiol Therapeutics Inc.?

The Commission File Number for Cardiol Therapeutics Inc. is 001-40712.

Does Cardiol Therapeutics Inc. file annual reports under Form 20-F or Form 40-F?

Cardiol Therapeutics Inc. indicates it files annual reports under Form 40-F.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on April 1, 2025 regarding Cardiol Therapeutics Inc. (CRDL).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing